MB "ANG Pharma" Finance - revenue, profit
EBITDA margin (%)
Register and
explore Okredo dataEBIT margin (%)
Register and
explore Okredo data| Indicator |
|---|
| Turnover (€) |
| Sales per employee (€) |
| Profit before tax (€) |
| Net Profit (€) |
| Profit per employee (€) |
| Total profitability (%) |
| Net profitability (%) |
| Equity (€) |
| Amounts Payable And Liabilities (€) |
| Non-current Assets (€) |
| CurrentAssets (€) |
| Working capital requirement |
| Debt-to-equity ratio |
| EBITDA margin (%) |
| EBITDA (€) |
| EBIT margin (%) |
| EBIT (€) |
| 2023 |
|---|
| 38,045 |
| - |
| 7,853 |
| 7,693 |
| - |
| 63.90 |
| 20.22 |
| 1,785 |
| 25,906 |
| 0 |
| 27,691 |
| 0.60 |
| 14.51 |
| - |
| - |
| 20.64 |
| 7,853 |
| 2024 |
|---|
| 31,602 |
| - |
| 5,382 |
| 5,147 |
| - |
| 65.19 |
| 16.29 |
| 6,932 |
| 13,921 |
| 0 |
| 20,853 |
| 0.47 |
| 2.01 |
| - |
| - |
| 17.03 |
| 5,382 |
| 2025 |
|---|
| 35,735 |
| - |
| 8,316 |
| 7,828 |
| - |
| 65.86 |
| 21.91 |
| 14,760 |
| 9,758 |
| 0 |
| 24,518 |
| 0.50 |
| 0.66 |
| - |
| - |
| 23.27 |
| 8,316 |
| 2025 |
|---|
| 35,735 |
| - |
| 8,316 |
| 7,828 |
| - |
| 65.86 |
| 21.91 |
| 14,760 |
| 9,758 |
| 0 |
| 24,518 |
| 0.50 |
| 0.66 |
| - |
| - |
| 23.27 |
| 8,316 |
Turnover (€)
2025
Turnover (€)
35,735 €13 % *
Sales per employee (€)
-Profit before tax (€)
8,316 €55 % *
Net Profit (€)
7,828 €52 % *
Profit per employee (€)
-Total profitability (%)
65.86 %1.03 % *
Net profitability (%)
21.91 %34.50 % *
Equity (€)
14,760 €113 % *
Amounts Payable And Liabilities (€)
9,758 €-30 % *
Non-current Assets (€)
0 €- *
CurrentAssets (€)
24,518 €18 % *
Working capital requirement
0.50 6.38 % *
Debt-to-equity ratio
0.66 -67.16 % *
EBITDA margin (%)
-EBITDA (€)
-EBIT margin (%)
23.27 %36.64 % *
EBIT (€)
8,316 €55 % *
